JP2015519396A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519396A5
JP2015519396A5 JP2015517311A JP2015517311A JP2015519396A5 JP 2015519396 A5 JP2015519396 A5 JP 2015519396A5 JP 2015517311 A JP2015517311 A JP 2015517311A JP 2015517311 A JP2015517311 A JP 2015517311A JP 2015519396 A5 JP2015519396 A5 JP 2015519396A5
Authority
JP
Japan
Prior art keywords
cancer
compound
salt
inden
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517311A
Other languages
English (en)
Other versions
JP2015519396A (ja
JP6092376B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044211 external-priority patent/WO2013188184A1/en
Publication of JP2015519396A publication Critical patent/JP2015519396A/ja
Publication of JP2015519396A5 publication Critical patent/JP2015519396A5/ja
Application granted granted Critical
Publication of JP6092376B2 publication Critical patent/JP6092376B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (7)

  1. 3−[(1R)−6−フルオロ−2,3−ジヒドロ−1H−インデン−1−イル]−N−(3−メチル−1H−ピラゾール−5−イル)−3H−イミダゾ[4,5−b]ピリジン−5−アミンである化合物、またはその薬学的に許容される塩。
  2. 3−[(1R)−6−フルオロ−2,3−ジヒドロ−1H−インデン−1−イル]−N−(3−メチル−1H−ピラゾール−5−イル)−3H−イミダゾ[4,5−b]ピリジン−5−アミンである、請求項1記載の化合物。
  3. 3−[(1R)−6−フルオロ−2,3−ジヒドロ−1H−インデン−1−イル]−N−(3−メチル−1H−ピラゾール−5−イル)−3H−イミダゾ[4,5−b]ピリジン−5−アミンジヒドロクロリドである、請求項1記載の化合物。
  4. 請求項1〜3のいずれか一項に記載の化合物または塩と、薬学的に許容される担体、希釈剤または賦形剤とを含む医薬組成物。
  5. 治療に使用するための、請求項1〜3のいずれか一項に記載の化合物または塩。
  6. がんの治療に使用するための、請求項1〜3のいずれか一項に記載の化合物または塩。
  7. 前記がんが乳がん、肺がん、膵癌、腎がん、卵巣がん、前立腺がん、頭頸部がん、肝細胞癌および結腸がんからなる群から選択される、請求項6に記載の化合物または塩。
JP2015517311A 2012-06-14 2013-06-05 Jak1およびjak2の阻害剤 Expired - Fee Related JP6092376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659679P 2012-06-14 2012-06-14
US61/659,679 2012-06-14
PCT/US2013/044211 WO2013188184A1 (en) 2012-06-14 2013-06-05 Inhibitor of jak1 and jak2

Publications (3)

Publication Number Publication Date
JP2015519396A JP2015519396A (ja) 2015-07-09
JP2015519396A5 true JP2015519396A5 (ja) 2016-06-30
JP6092376B2 JP6092376B2 (ja) 2017-03-08

Family

ID=48626679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517311A Expired - Fee Related JP6092376B2 (ja) 2012-06-14 2013-06-05 Jak1およびjak2の阻害剤

Country Status (14)

Country Link
US (1) US9062050B2 (ja)
EP (1) EP2861231B1 (ja)
JP (1) JP6092376B2 (ja)
KR (1) KR20150008907A (ja)
CN (1) CN104349775B (ja)
AU (1) AU2013274641B2 (ja)
BR (1) BR112014030651A2 (ja)
CA (1) CA2871659C (ja)
EA (1) EA201492104A1 (ja)
ES (1) ES2605827T3 (ja)
IN (1) IN2014MN02228A (ja)
MX (1) MX2014015271A (ja)
WO (1) WO2013188184A1 (ja)
ZA (1) ZA201407940B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115141195B (zh) * 2021-03-03 2024-02-06 成都先导药物开发股份有限公司 一种nuak抑制剂及其用途
TW202325289A (zh) * 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Jak2抑制劑之形式及組合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2015519396A5 (ja)
IL288341B (en) Targeted ligands for medicinal compounds, methods for their preparation and uses thereof
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JP2014502638A5 (ja)
JP2017505782A5 (ja)
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2016501221A5 (ja)
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
JP2016533366A5 (ja)
NZ706836A (en) Methods of treating cancer
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP2017519027A5 (ja)
RU2016146119A (ru) Новый кристалл тетрациклического соединения
EA201391171A1 (ru) Формы рифаксимина и их применение
WO2013040227A3 (en) Therapeutic compounds
JP2013541586A5 (ja)
JP2014508784A5 (ja)
IL238722B (en) New annals of indole for the treatment of cancer, viral infections, and lung disease
JP2015506352A5 (ja)
JP2013540778A5 (ja)
HRP20191227T1 (hr) Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka
IL247567A0 (en) Process for liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2 and its salts suitable for pharmaceutical use